| Page 16 | Aplastic Anemia and MDS International Foundation

Patient-Reported Outcomes in Myelodysplastic Syndromes and MDS/MPN Overlap Syndromes: Stepping Onto the Stage with Changing Times

Author(s): 
Patel SS, Gerds AT
Primary Author: 
Patel SS
Journal Title: 
Curr Hematol Malig Rep
Original Publication Date: 
Aug 2017

Quality of life (QOL) and symptom burden are important measures captured by patient-reported outcomes (PROs). Myelodysplastic and myelodysplastic/myeloproliferative (MDS/MPN) neoplasm overlap syndromes are notable for significant morbidity and mortality, including a wide spectrum of physical and psychosocial effects. Thus, the development and application of PROs can provide meaningful information to facilitate communication and assist in follow up care. Disease-specific measures can more accurately reflect the full breadth of functional restrictions and symptoms.

Bone Marrow Diseases: 

Predictors of early mortality after rabbit antithymocyte globulin as first-line treatment in severe aplastic anemia

Author(s): 
Atta EH, Lima CBL, Dias DSP, Clé DV, Bonduel MM, Sciuccati GB, Medeiros LA, Oliveira MM, Salvino MA, Garanito MP, Blum Fonseca PB, Saad STO, Calado RT, Scheinberg P
Primary Author: 
Atta EH
Journal Title: 
Ann Hematol
Original Publication Date: 
Aug 2017

Despite being recommended as first-line immunosuppressive therapy in severe

Bone Marrow Diseases: 

Nivolumab-induced aplastic anemia: A case report and literature review

Author(s): 
Comito RR, Badu LA, Forcello N
Primary Author: 
Comito RR
Journal Title: 
J Oncol Pharm Pract
Original Publication Date: 
Aug 2017

Directed immunotherapy at the programmed cell death-1 receptor has demonstrated efficacy in non-small-cell lung cancer, metastatic melanoma, and various other malignancies. Immune checkpoint inhibitors are innovative therapies producing some impressive clinical responses with a more manageable adverse effect profile when compared to traditional

Bone Marrow Diseases: 

Clinical Outcomes in Adult Patients with Aplastic Anemia- a single institution experience

Author(s): 
Boddu P, Garcia-Manero G, Ravandi F, Borthakur G, Jabbour E, DiNardo C, Jain N, Daver N, Pemmaraju N, Anderlini P, Parmar S, Kc D, Akosile M, Pierce SA, Champlin R, Cortes J, Kantarjian H, Kadia T
Primary Author: 
Boddu P
Journal Title: 
Am J Hematol
Original Publication Date: 
Aug 2017

Newer treatment modalities are being investigated to improve upon historical outcomes with standard immunosuppressive therapy (IST) in

Bone Marrow Diseases: 

Newark

Thank you for attending the 2017 Patient and Family Conference in Newark, NJ.

Thank you for attending the 2017 Patient and Family Conference in Newark, NJ.
Event Date: 
Sat, 09/16/2017 -
8:00am to 3:30pm
Conference Event Type: 

A call for action: Increasing enrollment of untreated patients with higher-risk myelodysplastic syndromes in first-line clinical trials.

Author(s): 
Zeidan AM, Stahl M, Sekeres MA, Steensma DP, Komrokji RS, Gore SD
Primary Author: 
Zeidan AM
Journal Title: 
Cancer
Original Publication Date: 
Jul 2017

Hypomethylating agents (HMAs) have changed the landscape of the management of patients with higher-risk

Bone Marrow Diseases: